This study is testing if a medication called upadacitinib can help people with Eosinophilic Esophagitis (EoE), a condition where a type of white blood cell called eosinophils build up in the esophagus. The main goal is to see if adding upadacitinib to your current topical corticosteroid treatment reduces EoE activity. You would take upadacitinib or a placebo (a pill with no medicine) daily for 12 weeks, followed by 12 weeks where everyone receives upadacitinib. You'll also complete surveys and have regular check-ups and tests at the clinic every four weeks. This study is looking for participants aged 18 to 65 who have been diagnosed with EoE and are currently using topical corticosteroids.

Study design

This is an interventional study with a planned enrollment of 52 participants. It involves a 12-week blinded period where you might receive upadacitinib or a placebo, followed by a 12-week open-label period where all participants receive upadacitinib.

What's involved

You will take daily medication for 24 weeks, visit the clinic every 4 weeks for checkups and tests, and complete surveys. You will also have an upper endoscopy after each 12-week period.

Compensation

Not stated in the trial record.

Follow-up

You will have a final checkup 30 days after your last endoscopy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.